Recent Advances in Inflammation & Allergy Drug Discovery最新文献_第3页

Association between Cardiac Atrioventricular Conduction and Antibodies to Chlamydia Pneumoniae in Fibromyalgia Patients. 纤维肌痛患者心脏房室传导与肺炎衣原体抗体的关系

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230705140935

Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach

{"title":"Association between Cardiac Atrioventricular Conduction and Antibodies to Chlamydia Pneumoniae in Fibromyalgia Patients.","authors":"Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach","doi":"10.2174/2772270817666230705140935","DOIUrl":"10.2174/2772270817666230705140935","url":null,"abstract":"Background: Fibromyalgia patients may complain of cardiovascular symptoms, including chest pain and palpitations. It has been proposed that infection by Chlamydia pneumoniae might be common in fibromyalgia. Chlamydia pneumoniae infection has also been hypothesized to be a causative factor in cardiac disease.Objective: This study aims to test the hypothesis that there is an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia.Methods: Thirteen female fibromyalgia patients underwent serum Chlamydia pneumoniae IgG assays and 12-lead electrocardiography in a cross-sectional study. None of the patients was taking medication which might affect atrioventricular conduction, and none suffered from hypothyroidism, renal disease, hepatic disease, or carotid hypersensitivity.Results: There was a significant positive correlation between the PR interval duration and the serum Chlamydia pneumoniae IgG level (r = 0.650; p = 0.016).Conclusion: This study supports the hypothesis of an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia patients. It suggests that the higher the level of such antibodies, the greater the electrocardiographic PR interval, and therefore the slower the atrioventricular conduction. Potential pathophysiological mechanisms include a chronic inflammatory response to Chlamydia pneumoniae and the action of the bacterial lipopolysaccharide. The latter may involve stimulators of interferon genes, activation of the cardiac NOD-like receptor protein 3 inflammasomes, and downregulation of fibroblast growth factor 5 in the heart.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"127-132"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice. 新型n -芳基邻苯二胺衍生物在小鼠体内的镇痛活性。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230302145537

Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi

{"title":"In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice.","authors":"Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi","doi":"10.2174/2772270817666230302145537","DOIUrl":"10.2174/2772270817666230302145537","url":null,"abstract":"Background: A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity.Methods: In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H1NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control.Results: All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin.Conclusion: This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"121-126"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Complex Regional Pain Syndrome (CRPS): New Perspectives in the use of Sulfonamides as Modulators of P2X Receptors. 复杂局部疼痛综合征(CRPS)的治疗:磺胺类药物作为P2X受体调节剂的新视角

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320124000

Giulia Culletta, Anna Maria Almerico, Marco Tutone

引用次数: 0

Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in Salmonella Typhimurium: Biocomputational Methods. 鼠伤寒沙门菌效应诱导免疫刺激的病理生理结构:生物计算方法。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230515125053

Abhigyan Choudhury

{"title":"Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in Salmonella Typhimurium: Biocomputational Methods.","authors":"Abhigyan Choudhury","doi":"10.2174/2772270817666230515125053","DOIUrl":"10.2174/2772270817666230515125053","url":null,"abstract":"Introduction: The worldwide impact of the foodborne pathogen Salmonella can never be overstated, nor can be the fatal threat of septicemia in patients infected with its Typhimurium serovar. Behind the hyperimmune response in the case of septicemia lies a critical phenomenon of the bacterial pathogenic signals being sensed by different pattern recognition receptors, such as the Typhimurium effector proteins that are detected by toll-like receptors.Methods: To mitigate such a threat, precise structural and functional description of these effectors is necessary. The same has been addressed in this article using accelerated biocomputational techniques, beginning with the identification of the functional niche of the effectors and their influence over other proteins.Results: The molecular crystal structures were retrieved, and rigorous molecular docking experiments were conducted among the TLRs and effector proteins in order to examine the interactions. The interactions were thereby evaluated and screened according to their respective strengths using parameters including binding affinity, dissociation constant, hydropathy variation, etc. SopB effectors were found to be detected by three different TLR proteins and GtgE by two other TLRs, while SifA, SrfJ, and SsaV had only a single interacting TLR partner each. Interestingly, TLR9 presented lower sensitivity towards PAMPs of this bacterium.Conclusion: Normal modal analyses in combination with atomistic molecular dynamics simulations that tend to imitate natural cytosolic environments reveal stable and consistent interactions and realistic conformations among the effector-bound TLR complexes. The findings open up new avenues for the development of targeted therapies against Salmonella, which could significantly reduce the global burden of this foodborne pathogen.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"133-144"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed. 空气过敏原特异性免疫治疗和生物制剂联合给药:迫切需要重新考虑成本效益。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320153734

George N Konstantinou, Maria Petrodimopoulou

引用次数: 0

Nano-Phytopharmaceuticals in Inflammation. 炎症中的纳米植物药物。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230123121836

Akhila S, Remya K

{"title":"Nano-Phytopharmaceuticals in Inflammation.","authors":"Akhila S, Remya K","doi":"10.2174/2772270817666230123121836","DOIUrl":"https://doi.org/10.2174/2772270817666230123121836","url":null,"abstract":"Inflammation is a defense mechanism of the body against harmful stimuli/organisms. Even if it is the body's defense mechanism, these mediators may affect different ways in the human body and can lead to chronic disorders. The most common treatment strategy for the acute type of inflammation mainly includes synthetic chemical drugs; Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressant drugs whereas these synthetic drugs have many side effects, adverse effects, and limitations. Herbal drugs can be a promising alternative to these synthetic drugs but they too have limitations. Recent advances in the nanotechnology field can be combined with herbal drugs to overcome the limitations. Research works done on topical nanophyto pharmaceuticals for anti-inflammatory activity were compiled and in all the studies, clear evidence is indicated for the increased penetration, distribution, and increased efficacy of phytopharmaceuticals when formulated into nano dosage forms. Considering the adverse effects and limitations of most widely used synthetic drugs, topical nano Phyto pharmaceuticals can play a pivotal role in the local and systemic delivery of promising phytoconstituents to a specific site of the body.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"31-38"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Prognostic Role of Corticosteroid Administration in Hospitalized Patients with Severe COVID-19: A Cross-sectional Study. 皮质类固醇在重症新冠肺炎住院患者中的预后作用：一项跨部门研究。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/0127722708245041230921064257

Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Ali Moradi, Mohammad Moein Vakilzadeh, Zahra Mazloum Khorasani, Mahmoud Ghavi, Amirhossein Sahebkar

{"title":"The Prognostic Role of Corticosteroid Administration in Hospitalized Patients with Severe COVID-19: A Cross-sectional Study.","authors":"Mohammad Ali Yaghoubi, Hassan Mehrad-Majd, Ali Moradi, Mohammad Moein Vakilzadeh, Zahra Mazloum Khorasani, Mahmoud Ghavi, Amirhossein Sahebkar","doi":"10.2174/0127722708245041230921064257","DOIUrl":"10.2174/0127722708245041230921064257","url":null,"abstract":"Background and objective: The COVID-19 pandemic is a recent global issue with no established consensus on treatments. Therefore, the aim of this study was to assess the impact of corticosteroid (CS) pulses on the prognosis of COVID-19 patients admitted to hospitals.Methods: In this retrospective single-center cross-sectional study, we used hospital records of all consecutive patients aged 18 years or older admitted to the hospital from July 23rd to September 23rd, 2021. All patients included in the study had confirmed SARS-CoV-2 infection using polymerase chain reaction (PCR) testing and required hospitalization. Demographic and clinical information, as well as patient outcomes, were collected. Treatment details, including the type(s), cumulative doses, and duration of administered corticosteroids, were also recorded. CS pulse therapy was defined as the daily administration of 24 mg or more of dexamethasone or its equivalents.Results: A total of 500 patients with COVID-19 were included in this study, comprising 122 patients who received CS pulse therapy and 378 patients who did not. A higher mortality rate was observed in patients receiving CS pulse therapy (42.6%) compared to the other group (28%) (p =0.04). Additionally, logistic regression analysis showed an increased mortality risk in patients receiving CS pulse therapy in the crude model (OR=1.54, 95% CI: 1.01-2.27, p <0.01). However, after adjusting for confounding factors, such as mechanical ventilation and ICU admission, the results were reversed (OR=0.21, 95% CI: 0.07-0.62, p <0.01). ; Conclusion: In the findings of the current study, treatment with CS pulses was shown to significantly enhance recovery in patients with non-severe COVID-19.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"152-157"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 Associated Pancytopenia (CAP): A Clinical Impact. COVID-19相关性全血细胞减少症(CAP):临床影响

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221207094122

Jitendra Singh, Anju Dinkar, Nilesh Kumar, Kailash Kumar

{"title":"COVID-19 Associated Pancytopenia (CAP): A Clinical Impact.","authors":"Jitendra Singh, Anju Dinkar, Nilesh Kumar, Kailash Kumar","doi":"10.2174/2772270817666221207094122","DOIUrl":"https://doi.org/10.2174/2772270817666221207094122","url":null,"abstract":"Background: SARS-CoV-2 infection has mild and asymptomatic to critical clinical course affecting mainly the lungs. Few case reports of COVID-19-associated pancytopenia are reported, but a series of 18 cases is not described in the literature to date.Aims and objectives: This study aimed to investigate pancytopenia in COVID-19 and its correlation with severity and to explore the detailed clinical and biochemical information in COVID-19- associated pancytopenia. This study also highlights pancytopenia's rarity and prognostic value among COVID-19 patients.Materials and methods: This was a retrospective observational study conducted in a tertiary care centre at a level 3 COVID care facility that included adults of either sex having positive RT PCR for COVID-19 from October 2020 to May 2021. Data were collected from the online outpatient department and hospitalized patients.Results: A total of 18 cases were included in the study; 13 were males (72.2%). The mean age was calculated as 48.56 years. Cases were categorized as severe 13 (72.2%) and non-severe 5 (27.8%) disease on the first day of pancytopenia. The most common presentations were fever 18 (100%) and cough 18 (100%), followed by generalized weakness 16 (88.9%), breathlessness 15 (83.3%), and diarrhoea 10 (55.6%). One case died in the severe disease group. The mean of haemoglobin, leukocyte count, and platelets in severe vs non-severe disease were calculated as 8.59 vs 8.74, 2339 vs 2578, and 77769 vs 88600, respectively.Conclusion: Pancytopenia was more prevalent in severe disease and age group 40-60 years. CAP was most likely due to secondary bone marrow suppression. It has no prognostic value for disease outcomes.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"71-78"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9876411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-Inflammatory Therapeutics: Conventional Concepts and Future with Nanotechnology. 抗炎治疗:传统概念和纳米技术的未来。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221027154402

Manju Bernela, Priya Kaushal, Naveen Verma, Rajesh Thakur, Munish Ahuja, Pawan Kaur

{"title":"Anti-Inflammatory Therapeutics: Conventional Concepts and Future with Nanotechnology.","authors":"Manju Bernela, Priya Kaushal, Naveen Verma, Rajesh Thakur, Munish Ahuja, Pawan Kaur","doi":"10.2174/2772270817666221027154402","DOIUrl":"https://doi.org/10.2174/2772270817666221027154402","url":null,"abstract":"Anti-inflammatory therapies currently in use mainly include steroidal and non-steroidal drugs. Contrary to their side effects, the steroid hormones glucocorticoids, which are synthetic versions of natural cortisol, are nevertheless often employed to treat a variety of inflammatory disorders. Other drug class of choice is non-steroidal drugs which mainly target COX-2 and hence the synthesis of prostaglandins, particularly PGE2. To cure both the short-term effects of chronic inflammatory disorders and the long-term symptoms of acute inflammation, pharmaceutical chemists are in continuous search for more potent and less toxic agents. Apart from these two drug classes, phytochemicals are gaining the attention of researchers as source of alternative antiinflammatory agents. However, every drug class has its own advantages or disadvantages thus requiring intervention of newer approaches. Currently, drugs used for anti-inflammatory therapies are costly with low efficacy, high health risk, and socio-economic impact due to the concern issue of their toxicity. Recently, nano-drug delivery system has been experiencing main interest as a new approach for targeting therapeutic agents to the target sites in a controlled, sustained manner and has various advantages as compared to the conventional drug delivery system like, increased solubility, bioavailability, improved pharmacokinetic profile of drugs, surface area and rate of dissolution and additionally, overcomes the problems related to hydrophobicity, toxicity. Present review summarized the intervention of nanotechnology to overcome the limitations/ risk associated with current anti-inflammatory drugs of different classes.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"7-19"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9879879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19. 胆汁酸与SARS-CoV-2:熊去氧胆酸作为COVID-19的潜在治疗方法

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230601124326

Stefano Fiorucci, Ginevra Urbani, Eleonora Distrutti

引用次数: 1